Background. Intervention by infectious diseases (ID) physicians improves outcomes for inpatients in Medicare, but patients with other insurance types could fare differently. We assessed whether ID involvement leads to better outcomes among privately insured patients under age 65 years hospitalized with common infections.
Infectious diseases are a major cause of morbidity and mortality across all age groups. Physicians from multiple disciplines may participate in the care of patients with serious infections. There is an evolving body of literature suggesting that consultation by an Infectious Diseases (ID) physician contributes to positive health outcomes for common and serious infections.
In meta-analysis of 18 studies of hospitalized patients treated for Staphylococcus aureus bacteremia, patients who received ID intervention experienced lower 30-day mortality (relative risk [RR] 0.53, 95% confidence interval [CI] 0.43-0.65) and lower relapse rates (RR 0.62, 95% CI 0.39-0.99) [1] . In another study, ID intervention was associated with a 40% to 50% reduction in hospital-and 30-day mortality [2] . Similarly, among solidorgan-transplant recipients hospitalized for infection at 1 center, those receiving ID intervention had higher 28-day survival (hazard ratio 0.33) and reduced 30-day readmission rates (17% vs 24%) [3] .
Schmitt et al [4] reviewed Medicare claims data for people with any of 11 infections. ID involvement was associated with lower mortality and lower costs. Initial ID intervention within 2 days of admission was associated with better clinical outcomes than later involvement, although not with differences in cost or length of stay (LOS).
Previous studies in the United States have been limited to individual centers, infections, or to Medicare recipients. The current study extends them by assessing results associated with ID care in the general hospital population for privately insured individuals less than 65 years of age.
M A J O R A R T I C L E

METHODS
Study Design
We performed a retrospective analysis of administrative claims data. The study population consisted of individuals with any of a broad range of common infections, divided into 3 groups: those without ID physician intervention during the hospital stay, those with ID intervention early in the stay, and those with ID intervention later in the stay. Two sets of propensity-matched cohorts were developed: those with early intervention or no ID intervention, and those with early or later ID intervention. Using those pairs of cohorts, we then studied the relation between early ID intervention and health outcomes during the initial hospitalization and in the 30 days afterward.
Data Source
Analyses were performed on administrative claims from the Truven Health MarketScan™ Research Databases. The MarketScan Commercial Database contains the eligibility, inpatient, outpatient, and outpatient prescription-drug experience of employees and their dependents, covered under a variety of fee-for-service and capitated health plans. The MarketScan Medicare Supplemental Database contains the healthcare experience of individuals with Medicare supplemental insurance paid for by employers. Together they had over 30 million covered lives in 2014. We extracted claims from each database for events occurring between July 2012 and December 2014. All index events occurred in 2013 or 2014.
Inclusion and Exclusion Criteria
Index events consisted of inpatient stays in acute-care hospitals with a primary or secondary discharge diagnosis of any of the following: bacterial endocarditis, bacteremia, central-line-associated bloodstream infection (CLABSI), Clostridium difficile infection, meningitis, osteomyelitis, prosthetic joint infection, septic arthritis, septic shock, or vascular device infection. These were selected primarily on the basis of severity, frequency of occurrence, and the ability to clearly identify patients with these infections using ICD-9-CM codes.
Associated ICD-9-CM diagnosis codes appear in the Supplementary Appendix. A single patient could appear more than once in the data. Other inclusion criteria included continuous enrollment in the same health insurance plan for the 6 months prior to admission and for 30 days beyond discharge, medical or surgical admission type, and age less than 65 years at time of admission.
The age restriction excluded most Medicare recipients because enrollment before age 65 is limited to individuals with severe and persistent disability, less common in a data set of employed people and their dependents. Such patients appear in the MarketScan data if they also carried a Medicare supplemental insurance plan, in which case we observed the claims paid by that plan.
We also excluded patients if any of the following criteria applied: an acute-care hospitalization for any cause in the 30 days prior to the index stay, an acute-care hospitalization for the same cause as the index stay in the 6 months prior to the index stay, or discharge to another acute-care hospital from the index stay.
Variables
The initial analytic file included patient age group, sex, census division of the hospital, index stay type (medical or surgical), and whether the index stay was an observation stay. Several variables captured clinical characteristics of the index stay: infection (among those in Table 1 ), major diagnosis category (MDC), Elixhauser comorbidity index as modified by Quan et al [5] , number of 3-digit ICD-9-CM discharge diagnoses assigned, number of types of physician specialists consulted (a maximum of 27; see Supplementary Appendix for details), number of separate days on which the patient had an ID physician encounter, discharge status, average number of nonhospitalist encounters per day (expressed as deciles of that distribution), and whether the stay included time in intensive care. Payment models also featured an indicator of enrollment in a capitated health plan.
The key variable was intervention by an ID physician no later than the third day of the index stay, which we term "early intervention." Alternatives were later ID intervention, or none. The cutoff of 3 days was determined a priori by the investigators because the empiric choice of antimicrobial management and diagnostic testing with early ID interventions will likely have the greatest impact on the predetermined health outcomes.
We grouped age into 5 categories (0-17, 18-44, 45-54, 55-59, 60-64), and the Elixhauser comorbidity index was grouped into 4 (<0, 0-3, >3-8, >8). Negative values occur because some Elixhauser groups, such as obesity and depression, are assigned negative weights in the scoring algorithm [6] . Cost equaled the sum of payments by all payers, including the patient. A hospital was indicated as rural if it was located outside a metropolitan statistical area. Payment models also featured an indicator of enrollment in a capitated health plan.
Outcome variables were assessed during the index stay or the first 30 days after discharge. Outcomes for the index stay included mortality, length of stay, and cost. Postdischarge outcomes included mortality, hospital readmission for any cause, probability of any healthcare spending, and cost among those with postdischarge spending.
We performed analyses on 2 cohorts. The first, termed "early/ none, " consisted of people with early ID intervention and an equal number with no ID intervention at any time. A second, "early/late" cohort was composed of people with an early ID intervention and an equal number who had later ID intervention, defined as the 4th day or later. An individual with early ID intervention could appear in both cohorts.
To create each cohort, we used logistic regression to predict the likelihood of ID intervention. Regressors included the initial infection, Agency for Healthcare Research and Quality comorbidity indicators, the Charlson comorbidity index based on the 6 months prior to the index stay, patient age category, and sex, type of index stay, the rural status and geographic region of the hospital, and indicators for infection with methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and tuberculosis. The predicted likelihood of ID intervention for each case represented its propensity score. To create a balanced cohort, we matched cases 1-to-1 through nearest-neighbor matching without replacement, with a maximum difference in propensity score (caliper) of 0.03. Balance across matched cohorts was assessed by paired t-tests or χ 2 tests, standardized mean difference, and common support.
Statistical Analyses
For each cohort, we developed descriptive statistics for characteristics of the stay, person, and hospital. Separate regression models were run for each cohort and each outcome variable: logistic models for mortality and readmission models, negative binomial models for length of stay, and generalized linear models with log link and gamma distribution for spending models. All analyses were performed using SAS.
Research Ethics
The study funder, Infectious Diseases Society of America, participated in the study design and interpretation of results, and approved publication. Institutional Review Board approval was not required, but the study followed the principles of the Declaration of Helsinki.
RESULTS
We identified 76 608 index stays, of which 22 213 (29%) had an early ID intervention. Most variables were statistically significant in the propensity scoring models (see Supplementary Appendix). The matched early/none cohort had 11 438 stays, whereas the matched early/late cohort had 28 964. Cohorts were well balanced between those with and without early ID intervention. Standardized differences were <0.05 for all variables and were <0.04 for all but 2 variables in both cohorts. Table 1 presents the frequencies of the entry conditions in each matched cohort. Some individuals were diagnosed with 2 or more of these conditions. Bacteremia, osteomyelitis, and septic shock were the most common diagnoses. Bacterial endocarditis, C. difficile, and septic arthritis each accounted for more than 5% of patients in both cohorts. Transplants of heart, kidney, liver, or other solid organs accounted for 4%-6% of cases.
Fewer than 2% of individuals died during the initial hospital stay in both cohorts. Of those who survived, 16% in the early/none cohort had an inpatient or ED admission during the 30 days after discharge and 23% in the early/late cohort. Additional descriptive statistics appear in the Supplementary Appendix.
Early/No ID Comparison
Models of the index stay for the early/no ID cohort comparison appear in Table 2 Elixhauser scores, more diagnoses, more specialist types consulted, and vascular device infection. Stays with early ID intervention had an almost 23% shorter length of stay on average (incidence rate ratio [IRR] 0.772, 95% CI 0.755-0.790) relative to stays with no ID intervention. Longer length of stay was associated with Elixhauser scores of 3 or higher, rural location, markers of higher comorbidity (more diagnoses, more specialist types consulted, and more ID encounters), several different initial infections, and heart transplantation.
Similarly, early ID intervention was associated with a $10 888 decrement in spending during the index stay (95% CI $−11 651.88 to $−10 122.06), relative to stays with no ID intervention. Intensive care unit (ICU) stays and all transplant indicators were associated with much higher spending, as expected. In general, variables that predicted longer length of stay also predicted higher cost. Table 3 shows results of 3 regression models of the postdischarge period for the early/no ID cohort. Dashes indicate that a variable had to be dropped for the regression model to be estimated. Among those who survived the index stay, early ID intervention had a negative but insignificant association with postdischarge mortality (OR 0.754, 95% CI 0.468-1.273).
Likewise, higher numbers of ID encounters were not significantly associated with post-discharge mortality (OR 1.010, 95% CI 0.980-1.039). Higher mortality was associated with Elixhauser scores above 3, more diagnoses of any conditions, C. difficile infection, and vascular device infection.
Relative to those who had no ID intervention in the index stay, those who received early ID intervention had a lower readmission rate in the 30 days after discharge (OR 0.804, 95% CI 0.730-0.885) and lower total payments over that period (ME $−1841.54, 95% CI $−2852.14 to $−778.79). Higher readmission odds were associated with Elixhauser scores above 8, ICU stays, rural hospital location, greater comorbidity (more diagnoses, more specialist types consulted, and more ID encounters), certain diagnoses (bacterial endocarditis, CLABSI, osteomyelitis, and joint infection), and heart and liver transplants. Total payments were also much greater following observation stays than acute stays, although there was no relation to readmission. Tables 4 and 5 present similar figures for analyses of the early/ late ID cohort. During the initial stay, there was no significant relation of early ID intervention to mortality. Significant predictors of higher mortality included comorbidity measures (Elixhauser scores above 3, number of diagnoses, number of specialist types consulted), ICU stays, and selected diagnoses and procedures. Having more ID encounters was associated with lower mortality, all else being equal (OR 0.973, 95% CI 0.939-0.998). Similarly, early ID intervention was associated with significantly lower LOS (IRR 0.710, 0.695-0.796) and an associated reduction in the accrued costs (ME $−20 264.59, 95% CI $−21 702.94 to $−18 813.11) during the initial stay. Longer length of stay and higher cost were significantly related to higher comorbidity (higher Elixhauser scores, more diagnoses, encounters with more specialist types), more ID encounters, having an ICU stay, most transplant types, and diagnoses of meningitis or septic shock.
Early/Late Comparison
In the 30 days after discharge, early ID intervention was associated with significantly lower odds of mortality (OR 0.629, 95% CI 0.364-0.982), lower odds of readmission (OR 0.816, 95% CI 0.741-0.898), and lower spending (ME $−2312.19, 95% CI $−3409.94 to $−1018.77). Other significant predictors of mortality included Elixhauser score >8, number of diagnoses, number of ID encounters, and septic shock. A similar pattern emerged for readmission. Higher 30-day total payments were associated with greater comorbidity (Elixhauser score over 3, more diagnoses, encounters with more specialist types, and more ID encounters), ICU stay, observation status in the initial stay, the West region, CLABSI, and joint infection.
DISCUSSION
This study contributes to the understanding of how ID physician intervention benefits hospital patients with infection. First, although many studies have been limited to S. aureus bacteremia [1, 2, 7, 8] , here we broaden the focus to include a larger set of infectious disease conditions. Second, the current study distinguishes between later ID intervention and none. Although early ID intervention is associated with significant benefits relative to both other groups, the relative impact is different.
The current study complements earlier findings by Schmitt et al [4] , which took a similar approach but considered patients covered by Medicare, most of whom are at least 65 years of age. Two earlier studies considered the impact of ID consultation on multiple types of infection and without regard to insurance coverage. One found that patients with solid-organ transplants who were hospitalized for infection experienced lower mortality and lower 30-day rehospitalization rates if they received ID consultation than if they did not [3] . Among patients of a large cancer center who were infected with Candida glabrata, those who received ID consultation were more likely to receive appropriate antimicrobial therapy; those who had ID consultation within 48 hours had lower mortality as well [9] . However, these 2 studies were limited to a single hospital each, which could limit their generalizability.
We lacked the precise clinical data necessary to investigate the reasons for the better outcomes observed. Previous studies, however, have indicated that when treating infections, particularly S. aureus bacteremia, ID physicians are more likely than other physicians to identify a removable focus of infection [7] . They are also more likely to select the most appropriate antimicrobial therapy and to prescribe it for optimal duration, which in turn can reduce the risk of recurrence and readmission [1, 2, 7, 10] .
Early ID intervention was associated with a much lower likelihood of hospital mortality than either late or no ID intervention. The mortality rate in our data-under 1.5% across the index stay and postdischarge period-was much lower than has been found in studies that focus exclusively on S. aureus (such as nearly 20% in Vogel et al [1] ). Our data consist of privately insured individuals, or their dependents, all of whom were less than age 65 years at the time of the index hospitalization.
They are likely to have fewer comorbid conditions than people 65 years and older, and in general have markedly lower mortality rates [11] .
Among those who had ID intervention at any time, a greater number of ID encounters during an admission appears to be a marker of higher acuity. In part this occurs by construction, as longer stays have more opportunities for intervention by all types of physicians. The association with lower mortality during the inpatient stay, though, is consistent with a beneficial impact of ID intervention.
Readmissions within 30 days of discharge appeared to be concentrated among patients with high levels of comorbidity. Three significant predictors in the readmissions model represent comorbidity: the number of 3-digit discharge diagnoses, an Elixhauser score above 8, and the count of specialist types seen during the index stay. Combined with the very low mortality in the 30 days after discharge, this may be another indication of the relatively good health of most individuals in the data prior to hospitalization.
We acknowledge several limitations of our analysis. Patients were not randomized to early ID intervention, and patients within each cohort could differ by unobserved factors that relate to the measured outcomes. The definition of early intervention was necessarily arbitrary; other periods, such as 2 or 4 full days of stay, could lead to new conclusions. Claims data do not capture clinical situations perfectly, which could lead to misperception of a patient's clinical acuity. The generalizability of these results may be limited due to the inability of the data to answer key questions about prognosis and specific patient comorbidities or characteristics. Nevertheless, we do not expect that any inaccuracy varied by whether or when a patient received ID intervention. The study was not designed to detect the precise components of costs that were saved in infection treatment, and delineation of these factors is a topic for future investigation.
CONCLUSION
Among privately insured individuals below the age of 65 years treated in a hospital, intervention by an ID physician within the first 3 days of stay is associated with lower mortality rate, shorter length of stay, and lower costs. Results are broadly similar in comparison to people with later ID intervention or to people with no ID intervention during the initial stay. The impact of ID intervention extends beyond the initial hospitalization. Those who received early ID intervention during the initial hospital stay were also less likely to be readmitted in the 30 days after discharge and had lower total healthcare spending over the period, than people with late or no ID intervention. These findings add to the growing body of literature illustrating the benefit of early ID intervention on patient outcomes for a wide range of infections [1, 2, 4, 8, 10] . 
